Han Kun provides IP counsel to 3D Medicines for its listing in Hong Kong
December, 2022 - Beijing, Mainland China
Han Kun has advised and acted as the IP counsel to 3D Medicines Inc. ("3D Medicines", Stock Code: 1244.HK) for its initial public offering and listing on the Main Board of the Stock Exchange of Hong Kong ("HKEX").
3D Medicines is a bio-pharmaceutical company focusing on the research and development of oncology therapies for cancer patients. The company has built a pipeline consisting of one core product and 11 drug candidates, among which, the core product envafolimab (brand name: ENWEIDA, 恩维达®), as its backbone, was approved in November 2021 and commercialized in December 2021, and seven other drug candidates are in clinical stage.
Han Kun advised 3D Medicines on its listing, with the firm's biomedical and IP team providing relevant legal services throughout the listing process, including product pipeline FTO analysis, patent portfolio analysis, review of IP-related agreements and relevant prospectus sections, and assistance in replying to HKEX's inquiries.
